AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MAYNE PHARMA GROUP LTD

3.000

-0.180-5.66%

Volume:450.66K

Turnover:1.38M

Market Cap:245.67M

PE:14.45

High:3.170

Open:3.150

Low:2.990

Close:3.180

52wk High:6.500

52wk Low:2.040

Shares:81.89M

Float Shares:67.00M

Volume Ratio:1.34

T/O Rate:0.67%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.208

EPS(LYR):0.208

ROE:8.20%

ROA:-1.73%

PB:0.63

PE(LYR):14.45

Loading ...

Overview Company News Filings

Mayne Pharma Group - Minimal Impact Expected in Salisbury, South Australia Manufacturing Facility as Most Export Products to US Are Generic Products

THOMSON REUTERS

Mayne Pharma - Several of Company's Branded Dermatology Products May Be Subject to New Section 232 Tariffs

THOMSON REUTERS

Mayne Pharma Group Ltd-Non-Executive Director Retirement and Recruitment

THOMSON REUTERS

Inhibitor Therapeutics sues investor over failed $3 million stock financing

Inhibitor Therapeutics advances itraconazole PK trial for Gorlin syndrome ahead of NDA submission

Inhibitor Therapeutics FY2025 operating loss rises to $3.3 million; interest income drops 66.67% to $0.1 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/MYX.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MYX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","market":"AU","secType":"STK","nameCN":"MAYNE PHARMA GROUP LTD","latestPrice":3,"timestamp":1789020720000,"preClose":3.18,"halted":0,"volume":450658,"delay":0,"changeRate":-0.05660377358490571,"nameEN":"MAYNE PHARMA GROUP LTD","floatShares":66997185,"shares":81890887,"eps":0.207588,"marketStatus":"Not Yet Opened","change":-0.18,"latestTime":"09-10 16:12:00 AEST","open":3.15,"high":3.17,"low":2.99,"amount":1384986,"amplitude":0.056604,"askPrice":3.13,"askSize":10000,"bidPrice":2.98,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":0.207588,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":3.18,"openAndCloseTimeList":[[1788998400000,1789020000000]],"volumeRatio":1.3428978901584274,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MYX.AU","preClose":3.18,"auctionPrice":3.01,"auctionVolume":2361,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020602497}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MYX.AU\",,,,,undefined,":{"symbol":"MYX.AU","floatShares":66997185,"roa":"-1.73%","roe":"8.20%","lyrEps":0.207588,"volumeRatio":1.3428978901584274,"shares":81890887,"dividePrice":0,"high":3.17,"amplitude":0.056604,"preClose":3.18,"low":2.99,"week52Low":2.04,"pbRate":"0.63","psRate":"0.64","week52High":6.5,"institutionHeld":0,"latestPrice":3,"committee":-0.333333,"eps":0.207588,"divideRate":0,"volume":450658,"delay":0,"ttmEps":0.207588,"open":3.15,"prevYearClose":3.11,"prevWeekClose":3.11,"prevMonthClose":3.1,"prevQuarterClose":2.79,"fiveDayClose":3.11,"twentyDayClose":3.24,"sixtyDayClose":2.36,"dividendPayoutRate":0.04569711225089115,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.014818181818181815},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MYX.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-27","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787788800000,"name":null,"time":"","dateTimestamp":1787752800000,"actualEps":null},{"date":"2026-02-22","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771714800000,"name":null,"time":"","dateTimestamp":1771678800000,"actualEps":null},{"date":"2025-08-29","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756425600000,"name":null,"time":"","dateTimestamp":1756389600000,"actualEps":null},{"date":"2025-02-26","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null},{"date":"2024-08-23","symbol":"MYX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724371200000,"name":null,"time":"","dateTimestamp":1724335200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MYX.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2023-01-18","recordDate":"2023-01-19","paymentDate":"2023-01-27","value":0.038,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MYX.AU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625600102","title":"Mayne Pharma Group -  Minimal Impact Expected in Salisbury, South Australia Manufacturing Facility as Most Export Products to US Are Generic Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2625600102","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625600102?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:41","pubTimestamp":1775518913,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0KI:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625460018","title":"Mayne Pharma -  Several of Company's Branded Dermatology Products May Be Subject to New Section 232 Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2625460018","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625460018?lang=en_us&edition=fundamental","pubTime":"2026-04-07 07:41","pubTimestamp":1775518913,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nFWN40P0KI:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MYX.AU","BK7096","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624331526","title":"Mayne Pharma Group Ltd-Non-Executive Director Retirement and Recruitment","url":"https://stock-news.laohu8.com/highlight/detail?id=2624331526","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624331526?lang=en_us&edition=fundamental","pubTime":"2026-04-02 09:33","pubTimestamp":1775093593,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nTUE1Z01QP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7096","MYX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624491315","title":"Inhibitor Therapeutics sues investor over failed $3 million stock financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624491315","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624491315?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:08","pubTimestamp":1775074095,"startTime":"0","endTime":"0","summary":"Inhibitor Therapeutics filed litigation on March 30, 2026 against an institutional investor tied to a failed financing.Transaction contemplated sale of 12,000,000 common shares at $0.25 per share.Financing also included a warrant to buy up to 7,000,000 additional shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibitor Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL6LspBl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","INTI","BK4139","MYX.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624550074","title":"Inhibitor Therapeutics advances itraconazole PK trial for Gorlin syndrome ahead of NDA submission","url":"https://stock-news.laohu8.com/highlight/detail?id=2624550074","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624550074?lang=en_us&edition=fundamental","pubTime":"2026-04-01 09:58","pubTimestamp":1775008699,"startTime":"0","endTime":"0","summary":"Inhibitor Therapeutics outlined progress in a comparative pharmacokinetic clinical study for its proprietary itraconazole formulation in Gorlin syndrome, positioning it as final clinical step before a planned US NDA filing via FDA 505 pathway.Top-line comparative PK and relative bioavailability results will be presented in the future, expected around mid-May 2026, ahead of full clinical study report.Program aims to support more consistent drug exposure versus conventional itraconazole, using an amorphous formulation designed to improve solubility and absorption.Company also plans to file a new global patent application covering formulation composition, targeting stronger IP protection without ongoing royalty obligations if granted.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL4cdwxC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","MYX.AU","SG9999014021.USD","LU2095319765.USD","BK4139","BK4112","INTI","IE00BGHQF748.EUR","NDAQ","SG9999014013.SGD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4585","LU2210149790.SGD","BK4588","BK7508","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","SG9999014039.USD","IE00BN0W2V16.EUR","LU0314104364.USD","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622855234","title":"Inhibitor Therapeutics FY2025 operating loss rises to $3.3 million; interest income drops 66.67% to $0.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622855234","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622855234?lang=en_us&edition=fundamental","pubTime":"2026-03-26 18:04","pubTimestamp":1774519475,"startTime":"0","endTime":"0","summary":"Inhibitor Therapeutics published its annual report on Form 10-K.Net loss was USD 3.3 million and operating cash flow was negative USD 3.2 million.Research and development expense fell 5.56% to USD 1.7 million, driven by lower internal personnel costs tied to the relative significance of R&D activity and developments during the year.General and administrative expense decreased 10.53% to USD 1.7 million, reflecting lower compensation costs and insurance costs.Management said it expects additional losses and that liquidity is insufficient for the next 12 months, and noted a registered direct offering agreement for USD 3.0 million in proceeds intended for working capital and general corporate purposes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or lega","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL8NdxCT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MYX.AU","BK4139","BK7508","INTI","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":46,"code":"91000000","status":"200"}]}}